Kalaris Therapeutics (NASDAQ:KLRS) Research Coverage Started at Citizens Jmp

Citizens Jmp started coverage on shares of Kalaris Therapeutics (NASDAQ:KLRS) in a research report sent to investors on Monday, Marketbeat Ratings reports. The firm issued a market outperform rating and a $20.00 target price on the stock.

Several other research analysts also recently weighed in on KLRS. Wall Street Zen raised shares of Kalaris Therapeutics to a “hold” rating in a research report on Friday, October 3rd. Citigroup assumed coverage on Kalaris Therapeutics in a report on Monday. They issued an “outperform” rating for the company. Piper Sandler set a $3.00 price target on Kalaris Therapeutics and gave the company a “neutral” rating in a research report on Wednesday, July 23rd. Raymond James Financial initiated coverage on Kalaris Therapeutics in a research report on Tuesday, September 2nd. They set a “strong-buy” rating for the company. Finally, Weiss Ratings reiterated a “sell (e)” rating on shares of Kalaris Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $11.50.

Kalaris Therapeutics Price Performance

Shares of NASDAQ:KLRS opened at $5.00 on Monday. The firm has a market cap of $93.50 million, a P/E ratio of -1.23 and a beta of 0.42. The firm’s fifty day moving average is $4.96. Kalaris Therapeutics has a one year low of $2.14 and a one year high of $23.69.

Kalaris Therapeutics (NASDAQ:KLRS) last announced its earnings results on Wednesday, August 13th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.10).

Hedge Funds Weigh In On Kalaris Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KLRS. XTX Topco Ltd bought a new stake in Kalaris Therapeutics in the second quarter worth approximately $65,000. Belpointe Asset Management LLC bought a new stake in Kalaris Therapeutics in the third quarter worth $231,000. Finally, Fortis Capital Advisors LLC acquired a new position in Kalaris Therapeutics during the third quarter worth $231,000. Institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.